Farmas USA

SGYP

Las previsiones según este analista (además de reiterar PT 11$):

BTIG analyst Timothy Chiang reiterated a Buy rating and $11 price target on Synergy Pharmaceuticals (NASDAQ:  SGYP) saying Trulance weekly Rx trends continue to track ahead of the firm projections.

Chiang said while shares Synergy have been under relentless pressure, the Trulance's peak sales potential remains at ~$500M by 2022.

Based on their analysis of prescription trends for Trulance (once-daily dosed plecanatide for the treatment of chronic constipation), they believe weekly run rate figures are now in excess of 800 prescriptions in its 9th week of launch. In addition, the remain confident in the Synergy's ability to meet the firm's CY17 Trulance sales estimate of ~$21.5M.

Refills, which is another item they are starting to track, have also begun to ramp. The analyst notes the most recent week ending May 19, Symphony Healthcare reported ~101 refills being dispensed. "We do think refills will be important to watch, as this is an indicator of patients continuing on Rx treatment," he commented.

https://www.streetinsider.com/dr/news.php?id=12960826&gfv=1

hay que subirse a esa línea verde pero ya, si no pues a 2.5x muy probable.

Synergy Pharmaceuticals (NASDAQ:SGYP) is up 2% premarket on modest volume on the heels of a note from BTIG Research's Timothy Chiang saying prescription trends for CIC med TRULANCE (plecanatide) are tracking ahead of projections, now more than 800/week. He adds that the company should be able to meet it 2017 sales estimate of ~$21.5M. Refills are also beginning to ramp.
• Mr. Chiang reiterates his peak sales estimate of ~$500M by 2022.
• Source: StreetInsider

Jaja, Jensen tiene un artículo (reciente) para todo...

https://seekingalpha.com/article/4071781-synergy-pharmaceuticals-overlooked-4-biopharma-stock

...este hombre se pasa de prolífico, más vale calidad que cantidad.

SGYP

nviv

como aguanta esos 1.95 llevo semanas con 1.7 y no hay manera, en cuanto compre se va  a 1.7 está esperándome :)

Jajaja, así, en alguna acertará

mack

lo que dije ayer lo ha hecho hoy, ahora falta el rebote, que no lo veo.

Gracias por el chart, las crispr (EDIT; NTLA,etc) son buenas para los que os gusta tradear. Como no tienen ningún producto en clínica aún, está bien para comprar cuando caen por una news mala o publicación en la edición gnética, y vender cuando suben por alguna noticia como la de las patentes de EDIT, etc. Aún falta mucho para que sean una realidad como terapia.